Anti-Aging · Reference
ASCEND Blend Dosage: The Four Peptides in Units, mL and mg
This page explains the ASCEND dosage Pepti prescribes, what the units on the syringe mean, how much of each peptide is in a dose, a dosage chart for the ASCEND vial, how an ASCEND dose compares with the products next to it, when it is taken, what can change your directions, and the side effects to know about. It covers how Pepti prescribes ASCEND, not online protocols. Nothing here is a reason to change your own dose.
At Pepti, the ASCEND blend is prescribed as 0.25 mL, which is 25 units on a U-100 insulin syringe, injected under the skin Monday through Friday nights at bedtime. The 5 mL vial holds 6 mg CJC-1295, 12 mg ipamorelin, 10 mg tesamorelin and 1 mg IGF-1 LR3, so every 0.25 mL dose delivers 0.3 mg CJC-1295, 0.6 mg ipamorelin, 0.5 mg tesamorelin and 0.05 mg (50 mcg) IGF-1 LR3, and the vial holds 20 doses, about four weeks. Your physician sets your directions after reviewing your intake, and your exact dose and units are printed on the vial. The four peptides are in fixed proportion, so every draw delivers the same split.
This page explains the ASCEND dosage Pepti prescribes, what the units on the syringe mean, how much of each peptide is in a dose, a dosage chart for the ASCEND vial, how an ASCEND dose compares with the products next to it, when it is taken, what can change your directions, and the side effects to know about. It covers how Pepti prescribes ASCEND, not online protocols. Nothing here is a reason to change your own dose.
ASCEND Blend Dosage
The short answer
| Product | Vial | Typical directions | Per dose | Doses per vial | Price |
|---|---|---|---|---|---|
| ASCEND Blend | 5 mL: CJC-1295 1.2 mg/mL, ipamorelin 2.4 mg/mL, tesamorelin 2 mg/mL, IGF-1 LR3 0.2 mg/mL | Inject 0.25 mL (25 units) subcutaneously Monday through Friday nights at bedtime | 0.3 mg CJC-1295, 0.6 mg ipamorelin, 0.5 mg tesamorelin, 0.05 mg IGF-1 LR3 | 20 | $289/mo |
The price is all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. These are the typical printed directions; your own directions are the ones on your vial.
ASCEND Blend Dosage
What ASCEND is, briefly
ASCEND is four independently studied peptides dissolved together in one sterile multi-dose vial. Three of them prompt the pituitary to release your own growth hormone: CJC-1295 and tesamorelin are analogues of growth-hormone-releasing hormone (GHRH) and act on the GHRH receptor, and ipamorelin acts on the ghrelin receptor, GHS-R1a, a second signal that converges on the same pulse. The fourth, IGF-1 LR3, is a modified version of IGF-1, the growth factor growth hormone mostly works through, built to escape the binding proteins that normally carry and buffer it. The name is a brand name for the combination; it does not appear in any journal, and the combination has never been studied as a combination. The full reference is what is ASCEND.
ASCEND Blend Dosage
ASCEND dosage in units, mL and mg
Pepti's directions are written in two forms, millilitres and units, because prescriptions are written in millilitres and insulin syringes are marked in units. On a U-100 insulin syringe, 1 unit is 0.01 mL, so 100 units is 1 mL and 25 units is 0.25 mL. A unit is a volume mark on the barrel, not a measure of how strong the medication is.
A four-peptide vial has four concentrations on its label, and each gives its own milligram figure from the same draw:
| Component | Concentration | Per vial | Per 0.25 mL dose |
|---|---|---|---|
| CJC-1295 | 1.2 mg/mL | 6 mg | 0.3 mg |
| Ipamorelin | 2.4 mg/mL | 12 mg | 0.6 mg |
| Tesamorelin | 2 mg/mL | 10 mg | 0.5 mg |
| IGF-1 LR3 | 0.2 mg/mL | 1 mg | 0.05 mg (50 mcg) |
| Total | 29 mg | 1.45 mg |
That arithmetic is a way to read a label, not a way to set a dose. A vial labelled 29 mg in total is not a 29 mg dose: it is twenty doses of 1.45 mg combined. If your label and your syringe seem to disagree, do not dose; message your care team. How long does a peptide vial last explains every number on a vial label.
Fixed proportions
The four peptides are in a ratio fixed by the pharmacy's formulation. Every dose delivers the same split, and there is no way to take more of one and less of another from the same vial. Ipamorelin is 12 of the 29 mg, tesamorelin 10, CJC-1295 6 and IGF-1 LR3 1 mg, about three percent by mass. By mass, ASCEND is a secretagogue preparation with a small direct IGF-1 component. If a different balance is wanted, the components are prescribed separately.
ASCEND Blend Dosage
ASCEND dosage chart: units to mL to mg
The chart below is the conversion for the ASCEND vial, drawn with a U-100 insulin syringe. It is math only. It is not a menu of doses, and the only line that applies to you is the one that matches the number printed on your vial.
| Syringe mark (U-100) | Volume | CJC-1295 | Ipamorelin | Tesamorelin | IGF-1 LR3 |
|---|---|---|---|---|---|
| 5 units | 0.05 mL | 0.06 mg | 0.12 mg | 0.1 mg | 0.01 mg (10 mcg) |
| 10 units | 0.1 mL | 0.12 mg | 0.24 mg | 0.2 mg | 0.02 mg (20 mcg) |
| 15 units | 0.15 mL | 0.18 mg | 0.36 mg | 0.3 mg | 0.03 mg (30 mcg) |
| 20 units | 0.2 mL | 0.24 mg | 0.48 mg | 0.4 mg | 0.04 mg (40 mcg) |
| 25 units (Pepti's typical directions) | 0.25 mL | 0.3 mg | 0.6 mg | 0.5 mg | 0.05 mg (50 mcg) |
| 50 units | 0.5 mL | 0.6 mg | 1.2 mg | 1 mg | 0.1 mg (100 mcg) |
| 100 units | 1 mL | 1.2 mg | 2.4 mg | 2 mg | 0.2 mg (200 mcg) |
The rule behind every row: units divided by 100 gives millilitres; multiply millilitres by 1.2 for CJC-1295, 2.4 for ipamorelin, 2 for tesamorelin and 0.2 for IGF-1 LR3. Those multipliers only hold for this vial. A chart written for a different blend or concentration gives different milligram figures for the same units. With IGF-1 LR3 in the vial, where the main caution is low blood sugar, that is the main reason not to dose from a chart, including this one.
ASCEND Blend Dosage
ASCEND compared with the products next to it
People often compare an ASCEND dose with CJC-1295 / Ipamorelin, with TITAN, or with the single peptides. The draw is 25 units in each, but what that draw delivers is different:
| ASCEND | CJC-1295 / Ipamorelin | TITAN | Tesamorelin | IGF-1 LR3 | |
|---|---|---|---|---|---|
| What is in the vial | 6 mg CJC-1295, 12 mg ipamorelin, 10 mg tesamorelin, 1 mg IGF-1 LR3 | 6 mg CJC-1295, 12 mg ipamorelin | 10 mg tesamorelin, 6 mg CJC-1295, 12 mg ipamorelin, 10 mg BPC-157 | 10 mg tesamorelin | 1000 mcg IGF-1 LR3 |
| Typical directions | 0.25 mL, weeknights at bedtime | 0.25 mL, once daily Monday through Friday on an empty stomach | 0.25 mL, weeknights at bedtime | 0.25 mL, weeknights at bedtime | 0.25 mL, weeknights at bedtime |
| Per dose | 0.3 mg CJC-1295, 0.6 mg ipamorelin, 0.5 mg tesamorelin, 50 mcg IGF-1 LR3 | 0.3 mg CJC-1295, 0.6 mg ipamorelin | 0.5 mg tesamorelin, 0.3 mg CJC-1295, 0.6 mg ipamorelin, 0.5 mg BPC-157 | 0.5 mg tesamorelin | 50 mcg IGF-1 LR3 |
| Price | $289/mo | $239/mo | $289/mo | $249/mo | $259/mo |
What the numbers show
ASCEND delivers exactly the same CJC-1295 and ipamorelin per dose as the two-peptide CJC-1295 / Ipamorelin vial, the same tesamorelin per dose as tesamorelin on its own, and the same IGF-1 LR3 per dose as the single IGF-1 LR3 vial. Nothing is diluted by being in a blend. That is also why ASCEND is not taken alongside any of those products: it would double a component. TITAN shares three components at the same amounts and swaps IGF-1 LR3 for BPC-157, which drops the blood sugar and growth-signalling cautions that come with IGF-1 LR3. PHYSIQ vs SHRED vs TITAN compares the neighbouring blends.
ASCEND Blend Dosage
How long an ASCEND vial lasts
| Step | Value |
|---|---|
| Dose | 25 units, 0.25 mL |
| Doses per week | 5 (Monday through Friday) |
| Doses per vial | 20 (5 mL divided by 0.25 mL) |
| Used over the vial | 6 mg CJC-1295, 12 mg ipamorelin, 10 mg tesamorelin, 1 mg IGF-1 LR3, the whole vial |
| Time per vial | 20 doses divided by 5 per week = 4 weeks |
Four weeks is why refills run every 28 days, one vial per fill. Vials are multi-dose solutions shipped ready to use, refrigerated with ice packs, with sterile syringes and alcohol prep pads. Nothing is mixed at home. Keep the vial in the fridge and follow the beyond-use date printed on the label, which runs from first puncture; a four-peptide vial is not something to keep past it. How to store peptides covers storage.
If a vial runs short before the refill, message your care team rather than adjusting anything yourself. If you miss a weeknight dose, follow your directions and do not take two doses to make up for one.
ASCEND Blend Dosage
When ASCEND is taken
At bedtime, Monday through Friday
The body's largest growth hormone pulse occurs in the first hours of slow-wave sleep, and the three secretagogues in ASCEND are dosed to reinforce it. Prescribers generally direct that the dose be taken away from food, because a rise in blood glucose and insulin blunts growth hormone release. The IGF-1 LR3 component is the reason a physician may qualify that if you have any tendency to low blood sugar, so follow the timing and food guidance in your own directions. Weekends off are part of the schedule, not missed doses, and the weekday pattern is a prescriber convention rather than something derived from a trial.
Under the skin
Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. Technique is in how to inject peptides safely.
| Directions say | What it means in practice |
|---|---|
| 0.25 mL (25 units) | Draw to the 25 mark on a U-100 insulin syringe |
| Subcutaneously | Into the fat layer, abdomen or thigh, rotating sites |
| Monday through Friday | Five doses a week, weekends off |
| Nights at bedtime | Shortly before sleep |
| 20 doses per vial | About four weeks, then the next refill |
ASCEND Blend Dosage
Why the research cannot give you an ASCEND dose
ASCEND has never been studied as a blend, in people or in animals, so there is no trial dose for it. The evidence is per component, and it is uneven:
| Component | Human dosing in the live research | How it compares with an ASCEND dose |
|---|---|---|
| Tesamorelin | 1 or 2 mg once daily in every trial, including 2 mg daily for 26 weeks (New England Journal of Medicine, 2007) | ASCEND delivers 0.5 mg five nights a week |
| CJC-1295 | Single injections of the DAC form in healthy adults (Journal of Clinical Endocrinology and Metabolism, 2006) | ASCEND contains the form without DAC, dosed nightly |
| Ipamorelin | Intravenous dosing in volunteers (Pharmaceutical Research, 1999) and after bowel surgery (2014) | ASCEND is subcutaneous |
| IGF-1 LR3 | Essentially no published human clinical studies | No human dose exists |
None of these used the weeknight schedule or the amounts in this vial, and none combined the peptides. The directions on the vial are a prescribing standard set to deliver one vial in four weeks. The evidence for each component is in tesamorelin dosage, ipamorelin dosage, what is CJC-1295 / Ipamorelin and what is IGF-1 LR3. What research has looked at, component by component, is in ASCEND blend benefits.
ASCEND Blend Dosage
What changes the directions
Your physician sets your directions after reviewing your intake. Things that can lead to different directions, or a different product, include:
| What can change | How it shows up |
|---|---|
| Whether ASCEND is the right formula | Visceral fat alone may point to tesamorelin; sleep and recovery without the IGF-1 question to CJC-1295 / Ipamorelin; a repair peptide rather than a growth factor to TITAN |
| Your blood sugar | Diabetes, impaired glucose tolerance, a tendency to low blood sugar, or insulin or another glucose-lowering medication change the conversation |
| Cancer history | A personal or family history of cancer is treated as a reason not to use this blend |
| Your other medications | Growth hormone can alter how some drugs are metabolised, so the intake asks for everything you take |
| How you respond | Puffiness, joint aches, hand tingling or any episode that could be low blood sugar go to your physician, who may revise your directions |
When directions change, the new numbers are printed on the new label. Never carry a number over from a previous fill. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.
ASCEND Blend Dosage
Side effects, in summary
| What is reported | What it means | What to do |
|---|---|---|
| Injection-site redness or soreness | The most common report | Rotate sites |
| A brief flush, headache, hunger after the dose | Reported with the secretagogues | Report it if it persists |
| Puffiness, joint aches, hand tingling | Classic growth hormone effects; usually more than the person needs | Message your care team; do not change the dose yourself |
| Shakiness, sweating, sudden hunger, confusion or light-headedness after a dose | Possible low blood sugar from IGF-1 LR3 | Eat or drink something with sugar, then contact your care team; call 911 for confusion that does not resolve or a seizure |
| Facial or throat swelling, widespread hives, breathing difficulty | Rare hypersensitivity | Emergency care first (call 911), then tell your physician |
Who should not take ASCEND, or should discuss it first: anyone with a personal or family history of cancer, diabetes or a tendency to low blood sugar, anyone on insulin or another glucose-lowering medication, anyone pregnant or breastfeeding, and tested athletes, because growth hormone secretagogues, GHRH analogues and IGF-1 analogues are prohibited in sport. The full list is in ASCEND blend side effects and IGF-1 LR3 side effects.
ASCEND is a compounded prescription; compounded medications are not FDA approved. An approved tesamorelin product exists for one specific indication, at a different dose; ASCEND itself is not approved for anything.
ASCEND Blend Dosage
Where to get ASCEND prescribed
ASCEND cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for what is in the vial: identity, purity, sterility and concentration are untested, so the per-dose figures above would not hold. The prescription route:
- Complete a free online intake covering your history, medications, blood sugar, cancer and family history, and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your physician stays reachable for questions and dose changes.
Pepti prescribes ASCEND in every state except Oklahoma, plus DC It is supplied as a vial and syringe only.
References
What this is based on.
References
- Falutz J, Allas S, Blot K et al.. Metabolic effects of a growth hormone-releasing factor in patients with HIV · N Engl J Med (2007) · PMID 18057338
- Raun K, Hansen BS, Johansen NL et al.. Ipamorelin, the first selective growth hormone secretagogue · Eur J Endocrinol (1998) · PMID 9849822
- Teichman SL, Neale A, Lawrence B et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · J Clin Endocrinol Metab (2006) · PMID 16352683
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
ASCEND Blend Dosage, answered.
At Pepti, 0.25 mL, which is 25 units on a U-100 insulin syringe, injected subcutaneously Monday through Friday nights at bedtime. Your physician sets your directions after reviewing your intake, and your exact dose is printed on the vial.
At 0.25 mL: 0.3 mg CJC-1295, 0.6 mg ipamorelin, 0.5 mg tesamorelin and 0.05 mg (50 mcg) IGF-1 LR3, 1.45 mg combined. The split is fixed by the formulation.
The number printed on your vial. Pepti's typical directions are 25 units, which is 0.25 mL on a U-100 insulin syringe.
Twenty. A 5 mL vial divided by 0.25 mL per dose is 20 doses, about four weeks at five nights a week.
The body's largest growth hormone pulse occurs during slow-wave sleep in the first hours of the night, and the secretagogues are dosed to reinforce it.
Prescribers generally direct that it be taken away from food, because a rise in blood sugar blunts growth hormone release. Because IGF-1 LR3 can lower blood sugar, follow the food guidance in your own directions, and ask before the first dose if it is unclear.
The CJC-1295 and ipamorelin per dose are identical. ASCEND adds 0.5 mg tesamorelin and 50 mcg IGF-1 LR3 to the same draw.
Raise it with your physician first. ASCEND already contains a full dose of each, so taking either alongside it doubles that component.
No. Take the dose printed on your vial, on the schedule printed on your vial. Puffiness and joint aches signal more growth hormone than a person needs, and IGF-1 LR3 brings a low blood sugar risk. If you have questions about your dose, message your care team.
No. Pepti vials are multi-dose solutions shipped ready to use, with sterile syringes and alcohol prep pads.
Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.